Application of Drug‐Coated Balloons in Complex High Risk and Indicated Percutaneous Coronary Interventions
Yvemarie B. O. Somsen,Tuomas T. Rissanen,Roel Hoek,Tijmen H. Ris,Wynand J. Stuijfzand,Alexander Nap,Sebastiaan A. Kleijn,José P. Henriques,Ruben W. de Winter,Paul Knaapen
DOI: https://doi.org/10.1002/ccd.31316
IF: 2.3
2024-12-13
Catheterization and Cardiovascular Interventions
Abstract:There is a growing trend of patients with significant comorbidities among those referred for percutaneous coronary intervention (PCI). Consequently, the number of patients undergoing complex high risk indicated PCI (CHIP) is rising. CHIP patients frequently present with factors predisposing to extensive drug‐eluting stent (DES) implantation, such as bifurcation and/or heavily calcified coronary lesions, which exposes them to the risks associated with an increased stent burden. The drug‐coated balloon (DCB) may overcome some of the limitations of DES, either through a hybrid strategy (DCB and DES combined) or as a leave‐nothing‐behind strategy (DCB‐only). As such, there is a growing interest in extending the application of DCB to the CHIP population. The present review provides an outline of the available evidence on DCB use in CHIP patients, which comprise the elderly, comorbid, and patients with complex coronary anatomy. Although the majority of available data are observational, most studies support a lower threshold for the use of DCBs, particularly when multiple CHIP factors coexist within a single patient. In patients with comorbidities which predispose to bleeding events (such as increasing age, diabetes mellitus, and hemodialysis) DCBs may encourage shorter dual antiplatelet therapy duration—although randomized trials are currently lacking. Further, DCBs may simplify PCI in bifurcation lesions and chronic total coronary occlusions by reducing total stent length, and allow for late lumen enlargement when used in a hybrid fashion. In conclusion, DCBs pose a viable therapeutic option in CHIP patients, either as a complement to DES or as stand‐alone therapy in selected cases.
cardiac & cardiovascular systems